15-Hydroxyprostaglandin Dehydrogenase in Osteoarthritis and Ankylosing Spondylitis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Osteoarthritis, Ankylosing Spondylitis. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
15-Hydroxyprostaglandin Dehydrogenase in Osteoarthritis and Ankylosing Spondylitis: Associations With Clinical and Musculoskeletal Ultrasound Features.
Overview
To evaluate serum and synovial fluid 15-PGDH levels in patients with osteoarthritis and ankylosing spondylitis and determine their associations with clinical and musculoskeletal ultrasound features. To compare 15-PGDH concentrations among patients with knee osteoarthritis, and ankylosing spondylitis with knee effusion To evaluate whether serum 15-PGDH reflects intra-articular 15-PGDH concentrations. Analysis the level of 15-PGDH in relation to disease activity and severity of both diseases.
Detailed description
Osteoarthritis (OA) and Ankylosing Spondylitis (AS) are chronic musculoskeletal disorders with different pathophysiology, clinical manifestations, and management strategies. OA is a degenerative joint disease in which inflammation also contributes to symptom severity and structural progression, while AS is a chronic inflammatory spondyloarthropathy characterized by axial inflammation and, in some patients, peripheral arthritis.
Prostaglandin E2 (PGE2) is a key mediator involved in pain, inflammation, and tissue remodeling in musculoskeletal disease. 15-hydroxyprostaglandin dehydrogenase (15-PGDH) is the major enzyme responsible for degradation of prostaglandins, especially PGE2, and therefore acts as an important regulator of prostaglandin activity in the joint microenvironment. In inflammatory arthritis, synovial studies have shown that 15-PGDH is present in healthy and inflamed synovial tissue, mainly in lining macrophages, fibroblasts, and vessels, supporting a possible role in local inflammatory regulation.
In osteoarthritis, experimental evidence indicates that 15-PGDH is biologically relevant to cartilage degeneration and repair, and inhibition of 15-PGDH may promote cartilage regeneration and reduce OA-associated pain. These findings support the rationale for investigating 15-PGDH as a biomarker in OA and AS.
Musculoskeletal ultrasound is a valuable non-invasive imaging tool in rheumatology and can detect synovial hypertrophy, effusion, and power Doppler activity. EULAR has published recommendations for standardized ultrasound procedures and reporting in rheumatic and musculoskeletal diseases, supporting its use in this study.
Accordingly, this study will assess serum and synovial fluid 15-PGDH levels in patients with OA and AS and examine their correlation with clinical and musculoskeletal ultrasound features.
Primary outcome measures
- Serum 15-hydroxyprostaglandin dehydrogenase (15-PGDH) levelr [Time frame: 2 years]
Eligibility criteria
Inclusion criteria
- Inclusion criteria
- Adults aged 18 years or older. AxSpA group Patients diagnosed as ankylosing spondylitis according to ASAS criteria . R OA group
- Adults with osteoarthritis Diagnosed according to the American College of Rheumatology classification criteria.\[8\]R ACR Clinical classification criteria for Osteoarthritis of the hip ACR Clinical classification criteria for Osteoarthritis of the knee ACR Clinical classification criteria for Osteoarthritis of the hand Control group Age- and sex-matched healthy controls.
Exclusion criteria
- • Other inflammatory arthritides such as psoriatic arthritis, gout, or SLE-related arthritis.
- Septic arthritis or suspected joint infection.
- Recent intra-articular steroid injection if it may influence biomarker results.
- Any major systemic illness likely to affect biomarker measurement or ultrasound interpretation.
- Patients received certain drugs as non-steroidal anti-inflammatory drugs (NSAIDs)
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-control
Study locations
Center list to be confirmed — check the primary protocol.
Publications
- Gheorghe KR, Sadique S, Leclerc P, Idborg H, Wobst I, Catrina AI, Jakobsson PJ, Korotkova M. Limited effect of anti-rheumatic treatment on 15-prostaglandin dehydrogenase in rheumatoid arthritis synovial tissue. Arthritis Res Ther. 2012 May 22;14(3):R121. doi: 10.1186/ar3851. PMID 22616846
- Kim HJ, Lee S, Lee HY, Won H, Chang SH, Nah SS. 15-hydroxyprostaglandin dehydrogenase is upregulated by hydroxychloroquine in rheumatoid arthritis fibroblast-like synoviocytes. Mol Med Rep. 2015 Sep;12(3):4141-4148. doi: 10.3892/mmr.2015.3931. Epub 2015 Jun 15. PMID 26082314
- Capkin E. Musculoskeletal ultrasonography in rheumatic diseases. Turk J Med Sci. 2023 Jul 20;53(6):1537-1551. doi: 10.55730/1300-0144.5723. eCollection 2023. PMID 38813491
Identifiers
NCT: NCT07751263 · OA-AS-15 PGDH